Basic Info
  • Factory Location: china

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: yes

    a microtubule inhibitor indicated for the treatment of:
    1.Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.Prior therapy should have included an anthracycline unless clinically contraindicated
    2.Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
    3.Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.

Send your message to this supplier
  • From:
  • To:
    SINOBRIGHT PHARMA CO.,LTD.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service